Study: New Medicine Service could save NHS England £517.6m

A scheme launched by the Department of Health in 2011 to help patients stick to their drug regimens has been so successful, that in its first five years, it will save NHS England £517.6m  in the long-term, a team of health economists has found.

Lead researcher Professor Rachel Elliott from The University of Manchester says the New Medicine Service (NMS) - a free scheme where community pharmacists help patients take new medicines - has improved medicines adherence by 10%.

The study was conducted by experts at The Universities of Manchester, Nottingham and a Patient and Public Representative.

Even in the short term, say the team, the scheme -where pharmacists are paid £24.60 each time they look after a patient as part of NMS has saved the NHS £75.4m.

The team used self-reported adherence at 10 weeks, considered the minimum time required to demonstrate behavioral change in a sample of 503 parents

She said: "On the basis of the evidence we have gathered for this research, we strongly recommend that NMS should continue to be commissioned in the future.

"Our study suggests NMS increased patient medicine adherence compared with normal practice, which translated into increased health gain at reduced overall cost.

"This is a simple intervention which has been popular with community pharmacists and patients and is transferable into most therapeutic areas.

"Some medicines, for example, can have early adverse effects but they subside over time such as anti-depressants.

"And we also believe these findings are likely to have applicability to other health care systems, including those based on insurance."

From inception of the NMS to the end of August 2016, 3.59 million consultations have been claimed for with over 820 000 in the year 2015/16.

Of 11,495 community pharmacies in England, 91.2% had delivered the NMS to at least one patient between November 2011 and January 2014.

She added: "These are significant benefits for two reasons because so many patients have experienced the service.

"We also think our figures are probably on the conservative side given probable patient recruitment bias, use of self-report of adherence, and the assumption that all the patients in the intervention arm actually received the NMS."

Non-adherence is common in diseases such as chronic obstructive pulmonary disease where only 33% of patients continue their drugs after 10 weeks. In schizophrenia, the figure is  52%,  asthma: 67%; and diabetes 78%.

According to previous research, the costs to NHS England of non-adherence is over £930 million per year in just five diseases: asthma, type 2 diabetes, high cholesterol/coronary heart disease, hypertension, and schizophrenia.

To tackle the problem -which causes reduced quality of life, increased hospitalizations and premature deaths -  the Department of Health launched the service six years ago.